Recently, the National Supplementary Health Agency (ANS) decided to include five new technologies aimed at treating cancer ovarian and gynecological in the List of Procedures and Events in Health. In total, 10 procedures and 20 drugs were added and will come into effect in 2022. Understand how the news can help.
Read more: Passed law that obliges health plans to cover more treatments
see more
'Barbie' movie predicted to boost Mattel profits…
Japanese company imposes time restriction and reaps benefits
New technologies in healthcare
The procedures to which health plan beneficiaries are entitled are present in the List of Health Procedures and Events. These processes are considered essential for the diagnosis, treatment and monitoring of diseases. In this way, people can orient themselves and search for more data efficiently and safely, all with a view to expanding access to information.
Recently announced developments include the levonorgestrel intrauterine delivery system (LNG-IUS), which is a device used to treat abnormal uterine bleeding; a genetic test for BRCA mutations, which is needed to determine which women qualify for cancer treatment with olaparib; in addition to liver radioembolization, which is nothing more than a radiotherapy procedure used to treat liver cancer.
Other new procedures have been added for two female cancers
The inhibitor olaparib was included for two different types of cancer in women: treatment for adult patients with endometriosis recurrent high-grade or serous ovarian cancer responding to platinum-based chemotherapy and for patient care adults with newly diagnosed high-grade ovarian cancer, provided they are advanced and respond to chemotherapy first line.
According to the ANS, job change proposals were submitted through an electronic form available at ANS official website and discussed in June and August. Two other suggested technologies were examined, but the results were unfavorable for inclusion in the Roster: a hormonal implant subdermal hormone of etonogestrel aimed at contraception and liver radioembolization for cases of colorectal cancer metastatic.
